||||||||||BI 764524 / Boehringer Ingelheim Enrollment open: A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy (clinicaltrials.gov) - May 22, 2024 P2, N=178, Recruiting, Sponsor: Boehringer Ingelheim The CRIMSON Phase 2b trial will study BI 764524 in patients with moderately severe/severe nonproliferative diabetic retinopathy. Not yet recruiting --> Recruiting